Patients with severe hypertriglyceridemia (sHTG) achieved an 83% median reduction in triglycerides (TG), with 96% of patients achieving TG levels below 500 mg/dL, a threshold associated with increased ...
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasisResults ...
Reported positive preclinical results for lead drug candidate EB-003, showing statistically significant improvements in animal models of severe chronic depression and despair and in post-traumatic ...
WHEAT RIDGE, CO / ACCESS Newswire / March 27, 2026 / Lifeloc Technologies, Inc. (OTC:LCTC), a global leader in the ...
Acquisition integrates patent-pending algorithms and data insight engine into PetaSight’s operating system so pharmaceutical ...
Homecare Feeding, Aging Population, and Technological Innovation Driving Global GrowthThe nasogastric intubation market is ...
Market OverviewThe global MedTech Contract Manufacturing Organization (CMO) market is witnessing robust growth, expanding at ...
For global buyers, the evolution of Chinese innovative drugs is no longer merely about “more choices” — it has become a ...
Electronic Caregiver is proud to sponsor the Synergy Home Care Annual Franchise Meeting LAS CRUCES, NM / ACCESS Newswire / March 27, 2026 / The home care industry is facing a paradox:Demand is ...
The European Investment Bank (EIB) has waived the put option attached to the warrants granted in connection with the €40 ...
The Phase 1 study of RLS-1496, the first human trial of a GPX4 (selective glutathione peroxidase 4) modulator, met its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results